<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766804</url>
  </required_header>
  <id_info>
    <org_study_id>OUH-HCA-002</org_study_id>
    <nct_id>NCT01766804</nct_id>
  </id_info>
  <brief_title>Effect of Bovine Colostrum on Toxicity and Inflammatory Responses</brief_title>
  <acronym>CALL</acronym>
  <official_title>Effect of Bovine Colostrum on Toxicity and Inflammatory Responses During Treatment of Childhood Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steffen Husby</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to evaluate the ability a colostrum containing diet to limit
      gastrointestinal toxicity including chemotherapy induced inflammation in children treated for
      acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute lymphoblastic leukaemia (ALL) is the most common form of childhood cancers. Cure rates
      are improving, but the intensity of treatment is limited by toxicity. 2-5% of patients die of
      treatment related complications, mostly related to therapy-induced toxicity and immune
      suppression. The aim of the present study is to evaluate the ability a colostrum containing
      diet to limit gastrointestinal toxicity including chemotherapy induced inflammation. The
      study is based on patients treated according to the current NOPHO protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days with fever. Fever</measure>
    <time_frame>Measured two times daily and on suspicion during the intervention period, up to four weeks,</time_frame>
    <description>Days with temperature at or above 38.5 degrees celsius.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days in intensive care unit</measure>
    <time_frame>During the 4 week intervention period</time_frame>
    <description>Number of days treated in an intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in i.v. antibiotic treatment.</measure>
    <time_frame>During the 4 week intervention period.</time_frame>
    <description>Number of days in intravenous antibiotic treatment during the intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of cytopenia (neutrocytes &lt;1,0 and platelets &lt;20)</measure>
    <time_frame>During the 4 week intervention period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proven or suspected infections</measure>
    <time_frame>During the 4 week intervention period</time_frame>
    <description>Episodes of suspected or culture positive sepsis number of documented septic events either culture proven or those treated with a course of antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blood and platelet transfusions given during the course of treatment</measure>
    <time_frame>During the 4 week intervention period.</time_frame>
    <description>Number of blood and platelet transfusions given during the course of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and paraclinical indices of gastrointestinal toxicity</measure>
    <time_frame>At base line and weekly during the 4 week intervention period. Up to 4 weeks.</time_frame>
    <description>Clinical toxicity is scored using Common Toxicity Criteria for Adverse Effects (NCI-CTCAE), WHO and oral mucositis assessment scale (OMAS) grading schemes at inclusion and weekly during the treatment period. Furthermore the patients register toxicity using the oral mucositis daily questionaire(OMDQ).
Paraclinical indices are citruline, fecal calprotectin,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serologic markers for systemic inflammation</measure>
    <time_frame>Weekly and at day 3 and 24, up to 4 weeks.</time_frame>
    <description>Serum will be taken weekly. Markers will include C reactive protein (CRP), procalcitonin (PCT), soluble urokinase plasminogen activator receptor (sUPAR), plasma cytokines and receptors (IL-6, IL-8, Soluble tumour necrosis factor receptors (sTNFR1), IL-1Ra).
Cytokine production in full blood cultures will be measured at day 3 and at day 24. Initial screening for a broad spectrum of cytokines will be performed in 5-10 patients. Based on these results a final panel of analyses comprising a narrower spectrum of cytokines will be determined and used for further investigation. These will include at least TNFR1, IL-1Ra, IL-6, IL-8.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Bovine colostrum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A daily supplement of bovine colostrum powder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A daily placebo supplement consisting of whole milk powder and whey protein.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bovine Colostrum</intervention_name>
    <description>The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.</description>
    <arm_group_label>Bovine colostrum</arm_group_label>
    <other_name>Colodan, Biodane-Pharma.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated according to the Nordic Society of Pediatric Haematology and Oncology
             (NOPHO) ALL protocol

        Exclusion Criteria:

          -  Milk Allergy

          -  Lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Rathe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University og Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Husby, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus MÃ¼ller, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peder S Wehner, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per T Sangild, DVSc, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Human Nutrition, Faculty of Life Science, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathias Rathe, MD</last_name>
    <phone>+4530296665</phone>
    <email>mathias.rathe@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steffen Husby, MD, DMSc</last_name>
    <email>steffen.husby@ouh.regionsyddanmark.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Rathe, MD</last_name>
      <phone>+4530296665</phone>
      <email>mathias.rathe@ouh.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Mathias Rathe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Rathe, MD</last_name>
      <phone>+4530296665</phone>
      <email>mathias.rathe@ouh.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Mathias Rathe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>October 3, 2016</last_update_submitted>
  <last_update_submitted_qc>October 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Steffen Husby</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Bovine Colostrum</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Infection</keyword>
  <keyword>Toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

